Back

Surrozen shares surge 98.45% after FDA trial application

Verifying
  • Surrozen submitted an FDA application to evaluate SZN-8141 for diabetic macular edema.
  • Shares rose 98.45% to $32.07 on Thursday, according to Benzinga Pro data.
  • Surrozen expects diabetic macular edema enrollment to begin by late 2026.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.